ENZARAD (ANZUP 1303) Trial
DOI: 10.1200/JCO-26-01794
8yFU
2y of enzalutamide to RT & 2y of ADT did not significantly improve metastasis-free survival or overall survival in the overall ENZARAD population.
Exception= cN1
Another Hypothesis perhaps
EASL–AASLD–ILCA consensus statement on HCC
Nature Reviews Clinical Oncology | Volume 23 | August 2026 | 619–647
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
MASTERPLAN Trial
Ph II (2:1) n=74
Median FU 3.2y
Periop chemotherapy ± stereotactic body radiotherapy (SBRT) in high-risk, localised pancreatic ductal adenocarcinoma (PDAC)
Absolute recurrence reduction: 31.8 percentage points @1y
[52% Vs 20.2%]
PFS /OS all pS in favour
ESMO 2026
TMH study
Unresectable LAHNSCC
Weekly C+P +OMC Vs. DCF
Non inferior
Low toxicity
Higher ORR
More conversion to resectability
NGS testing in HCC
Mets 1st Line = No role
Prior to 2nd / 3rd Line = Have a Clinical Path in mind. Don't blindly do it for all
ESMO / Pan Asia
Be realistic, Cautious & Judicious
Locoregional Therapies in HCC
How to choose ?
Which Shop to go to ?
Know thy weapons and its use
Individualise
MDT
Patient and Tumour factors
Mutually narrow down
HCC Vs Intrahepatic Cholangiocarcinoma
Typical Vs Atypical Features
Clinicians Dilemma !!!
When to do Biopsy
When not to do Biopsy
ESMO 2026
Key late Breaking Abstracts
Atypical EGFR mutation
Enozertinib: Birth of Redwood 1 (2027)
HERIZON-GEA-01
Her2+ GE Adenocarcinoma
Zoci: ES SCLC
Peritoneal Surface Malignancy
What non surgical Oncologist needs to know
PCI & scoring
CC scoring
And
Brief Overview of Randomised Trials
Cancer specific
Metastatic HCC
Patient Approach / Goals
How to approach in Clinic
Initial Assessment
Patient Selection on various Factors
1st L / 2 L sequencing Options
Dosing / Regimen
Trial evidence / efficacy
Keynote Toxicities to watch
Adjuvant therapy for intermediate-risk oral cancer
DOI:10.1016j.oraloncology.2024.106972.
Need of the hour is refining postoperative risk assessment in oral cavity cancer, but article does not resolve the controversy.
Extended FU.@Oct 2026
NRG BR002 trial
Does Ablating All Metastases Improve Outcomes in Oligometastatic Breast Cancer?
N=125 pts
Ph 2
Extended FU 57.5months
No.diff in PFS / OS
SAFFRON trial
ESMO 2026
Osimertinib plus savolitinib after osimertinib resistance in EGFR-mutant NSCLC
Phase III trial
First Glimpse
